Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer

EPMA Journal

Xianquan Zhan¹  Xiaowei Wang¹  Rong Hu¹ 

[1] State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, 410008, People’s Republic of China

关键词: Multi-parameter systematic strategy;    Systems biology;    Metabolomics;    Proteomics;    Transcriptomics;    Genomics;    Predictive, preventive and personalised medicine;   

Others  :  801917
DOI  :  10.1186/1878-5085-4-2

 received in 2012-12-19, accepted in 2013-01-09,  发布年份 2013

【 摘 要 】

Cancer is a complex disease that causes the alterations in the levels of gene, RNA, protein and metabolite. With the development of genomics, transcriptomics, proteomics and metabolomic techniques, the characterisation of key mutations and molecular pathways responsible for tumour progression has led to the identification of a large number of potential targets. The increasing understanding of molecular carcinogenesis has begun to change paradigms in oncology from traditional single-factor strategy to multi-parameter systematic strategy. The therapeutic model of cancer has changed from adopting the general radiotherapy and chemotherapy to personalised strategy. The development of predictive, preventive and personalised medicine (PPPM) will allow prediction of response with substantially increased accuracy, stratification of particular patient groups and eventual personalisation of medicine. The PPPM will change the approach to tumour diseases from a systematic and comprehensive point of view in the future. Patients will be treated according to the specific molecular profiles that are found in the individual tumour tissue and preferentially with targeted substances, if available.

【 授权许可】

   
2013 Hu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981, 66:1191-1308.
• [2]Pollack IF: Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. Neurosurg Pediatr 2011, 8:135-148.
• [3]Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M: The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer 2012, 19:R131-R147.
• [4]Friedl P, Alexander S: Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
• [5]Kang M, Buckley YM, Lowe AJ: Testing the role of genetic factors across multiple independent invasions of the shrub Scotch broom (Cytisus scoparius). Mol Ecol 2007, 16:4662-4673.
• [6]Jobling MA: The impact of recent events on human genetic diversity. Philos Trans R Soc Lond B Biol Sci 2012, 367:793-799.
• [7]Chen AY, Chen PM, Chen YJ: DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis 2012, 4:390-397.
• [8]McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007, 28:639-647.
• [9]Low YL, Wedren S, Liu J: High-throughput genomic technology in research and clinical management of breast cancer. Evolving landscape of genetic epidemiological studies. Breast Cancer Res 2006, 8:209. BioMed Central Full Text
• [10]Zhan X, Desiderio DM: The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas. EPMA J 2010, 1:439-459.
• [11]Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J 2012, 3:14. BioMed Central Full Text
• [12]Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
• [13]Chaffer CL, Weinberg RA: A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
• [14]Valastyan S, Weinberg RA: Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
• [15]Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L: Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 2012, 18:1109-1119.
• [16]Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010, 222:350-366.
• [17]Zhan X, Desiderio DM: Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics 2010, 3:13. BioMed Central Full Text
• [18]Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
• [19]Chen J: Multiple signal pathways in obesity-associated cancer. Obes Rev 2011, 12:1063-1070.
• [20]Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012, 30:777-782.
• [21]Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010, 16:6029-6039.
• [22]Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B: The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010, 24:1781-1784.
• [23]Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D: Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010, 16:5424-5435.
• [24]Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O: Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011, 17:2373-2384.
• [25]Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA: Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011, 13:384-392.
• [26]Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008, 68:206-215.
• [27]Longo DL: Tumor heterogeneity and personalized medicine. N Engl J Med 2012, 366:956-957.
• [28]Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM: Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res 2005, 65:10214-10222.
• [29]Samuel N, Hudson TJ: Translating genomics to the clinic: implications of cancer heterogeneity. Clin Chem 2013, 59:127-137.
• [30]Almendro V, Marusyk A, Polyak K: Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2012.
• [31]Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C: Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012, 18:5314-5328.
• [32]Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012, 12:323-334.
• [33]Damia G, D’Incalci M: Genetic instability influences drug response in cancer cells. Curr Drug Targets 2010, 11:1317-1324.
• [34]Hile SE, Shabashev S, Eckert KA: Tumor-specific microsatellite instability: do distinct mechanisms underlie the MSI-L and EMAST phenotypes? Mutat Res 2012.
• [35]Corcos D: Unbalanced replication as a major source of genetic instability in cancer cells. Am J Blood Res 2012, 2:160-169.
• [36]Pietras A: Cancer stem cells in tumor heterogeneity. Adv Cancer Res 2011, 112:255-281.
• [37]George O, Koob GF: Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev 2010, 35:232-247.
• [38]Gridelli C, Maione P, Colantuoni G, Rossi A: Chemotherapy of non-small cell lung cancer in elderly patients. Curr Med Chem 2002, 9:1487-1495.
• [39]Cosset JM, Mauch PM: The role of radiotherapy for early stage Hodgkin’s disease: limitations and perspectives. Ann Oncol 1998, 9:S57-S62.
• [40]Abraham I, El Sayed K, Chen ZS, Guo H: Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs 2012, 10:2312-2321.
• [41]Moncharmont C, Levy A, Gilormini M, Bertrand G, Chargari C, Alphonse G, Ardail D, Rodriguez-Lafrasse C, Magné N: Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett 2012, 322:139-147.
• [42]Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, Emam I, Farne A, Hastings E, Holloway E, Kurbatova N, Lukk M, Malone J, Mani R, Pilicheva E, Rustici G, Sharma A, Williams E, Adamusiak T, Brandizi M, Sklyar N, Brazma A: ArrayExpress update - an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res 2011, 39:D1002-D1004.
• [43]Chambers EV, Kindt AS, Semple CA: Opening sequence: computational genomics in the era of high-throughput sequencing. Genome Biol 2011, 12:310. BioMed Central Full Text
• [44]Wakefield MJ: Genomics - from Neanderthals to high-throughput sequencing. Genome Biol 2006, 7:326. BioMed Central Full Text
• [45]Ekmektzoglou KA, Samelis G, Karagiannis S, Zografos G, Xanthos T: Genomic instability in ulcerative colitis: a prerequisite for cancer in the inflammatory colon? Acta Gastroenterol Belg 2012, 75:293-299.
• [46]Giaretti W, Pentenero M, Gandolfo S, Castagnola P: Chromosomal instability, aneuploidy and routine high-resolution DNA content analysis in oral cancer risk evaluation. Future Oncol 2012, 8:1257-1271.
• [47]Sanchez-Pla A, Reverter F, Ruiz de Villa MC, Comabella M: Transcriptomics: mRNA and alternative splicing. J Neuroimmunol 2012, 248:23-31.
• [48]Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM, Oyesiku NM: Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary 2008, 11:231-245.
• [49]Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
• [50]Clark TA, Sugnet CW, Ares M Jr: Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science 2002, 296:907-910.
• [51]David L, Huber W, Granovskaia M, Toedling J, Palm CJ, Bofkin L, Jones T, Davis RW, Steinmetz LM: A high-resolution map of transcription in the yeast genome. Proc Natl Acad Sci U S A 2006, 103:5320-5325.
• [52]Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, Rinn JL, Tongprasit W, Samanta M, Weissman S, Gerstein M, Snyder M: Global identification of human transcribed sequences with genome tiling arrays. Science 2004, 306:2242-2246.
• [53]Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, Reinders MJ, Slootweg PJ, Holstege FC: An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005, 37:182-186.
• [54]Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, Sørlie T, Børresen-Dale AL, Gribbestad IS: Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer 2010, 10:628. BioMed Central Full Text
• [55]Okoniewski MJ, Miller CJ: Hybridization interactions between probesets in short oligo microarrays lead to spurious correlations. BMC Bioinforma 2006, 7:276. BioMed Central Full Text
• [56]Royce TE, Rozowsky JS, Gerstein MB: Toward a universal microarray: prediction of gene expression through nearest-neighbor probe sequence identification. Nucleic Acids Res 2007, 35:e99.
• [57]Zhan X, Desiderio DM: Comparative proteomics analysis of human pituitary adenomas: current status and future perspective. Mass Spectrom Rev 2005, 24:783-813.
• [58]Sabidó E, Selevsek N, Aebersold R: Mass spectrometry-based proteomics for systems biology. Curr Opin Biotechnol 2012, 23:591-597.
• [59]Bensimon A, Heck AJ, Aebersold R: Mass spectrometry-based proteomics and network biology. Annu Rev Biochem 2012, 81:379-405.
• [60]Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
• [61]Zhan X, Desiderio DM: Heterogeneity analysis of the human pituitary proteome. Clin Chem 2003, 49:1740-1751.
• [62]Desiderio DM, Zhan X: A study of the human pituitary proteome: the characterization of differentially expressed proteins in an adenoma compared to a control. Cell Mol Biology 2003, 49:689-712.
• [63]Liu J, Zhan X, Li M, Li G, Zhang P, Xiao Z, Shao M, Peng F, Hu R, Chen Z: Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. BMC Med Genomics 2012, 5:62. BioMed Central Full Text
• [64]Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF 3rd, Zhao Y: 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002, 1:117-124.
• [65]Shiio Y, Aebersold R: Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc 2006, 1:139-145.
• [66]Schrimpf SP, Meskenaite V, Brunner E, Rutishauser D, Walther P, Eng J, Aebersold R, Sonderegger P: Proteomic analysis of synaptosomes using isotope-coded affinity tags and mass spectrometry. Proteomics 2005, 5:2531-2541.
• [67]Munday DC, Surtees R, Emmott E, Dove BK, Digard P, Barr JN, Whitehouse A, Matthews D, Hiscox JA: Using SILAC and quantitative proteomics to investigate the interactions between viral and host proteomes. Proteomics 2012, 12:666-672.
• [68]Rao KC, Palamalai V, Dunlevy JR, Miyagi M: Peptidyl-Lys metalloendopeptidase-catalyzed 18O labeling for comparative proteomics: application to cytokine/lipolysaccharide-treated human retinal pigment epithelium cell line. Mol Cell Proteomics 2005, 4:1550-1557.
• [69]Miyagi M, Rao KC: Proteolytic 18O-labeling strategies for quantitative proteomics. Mass Spectrom Rev 2007, 26:121-136.
• [70]Chaerkady R, Pandey A: Applications of proteomics to lab diagnosis. Annu Rev Pathol 2008, 3:485-498.
• [71]Chen X, Sun L, Yu Y, Xue Y, Yang P: Amino acid-coded tagging approaches in quantitative proteomics. Expert Rev Proteomics 2007, 4:25-37.
• [72]Lee JY, Pajarillo EA, Kim MJ, Chae JP, Kang DK: Proteomic and transcriptional analysis of Lactobacillus johnsonii PF01 during bile salt exposure by iTRAQ shotgun proteomics and quantitative RT-PCR. J Proteome Res 2013, 12:432-443.
• [73]Jankova L, Chan C, Fung CL, Song X, Kwun SY, Cowley MJ, Kaplan W, Dent OF, Bokey EL, Chapuis PH, Baker MS, Robertson GR, Clarke SJ, Molloy MP: Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol Biosyst 2011, 7:2997-3005.
• [74]Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL, Samatova NF: Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 2006, 5:2909-2918.
• [75]Gao BB, Stuart L, Feener EP: Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome: application on angiotensin II-stimulated smooth muscle cells secretome. Mol Cell Proteomics 2008, 7:2399-2409.
• [76]Rabilloud T: Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2002, 2:3-10.
• [77]Cravatt BF, Simon GM, Yates JR III: The biological impact of mass-spectrometry-based proteomics. Nature 2007, 450:991-1000.
• [78]Domon B, Aebersold R: Mass spectrometry and protein analysis. Science 2006, 312:212-217.
• [79]Scigelova M, Makarov A: Orbitrap mass analyzer - overview and applications in proteomics. Proteomics 2006, 6(Suppl 2):16-21.
• [80]Schmidt A, Gehlenborg N, Bodenmiller B, Mueller LN, Campbell D, Mueller M, Aebersold R, Domon B: An integrated, directed mass spectrometric approach for in-depth characterization of complex peptide mixtures. Mol Cell Proteomics 2008, 7:2138-2150.
• [81]Zhan X, Desiderio DM: A reference map of a human pituitary adenoma proteome. Proteomics 2003, 3:699-713.
• [82]Zhan X, Evans CO, Oyesiku NM, Desiderio DM: Proteomics and transcriptomics analyses of secretagogin down-regulation in human non-functional pituitary adenomas. Pituitary 2003, 6:189-202.
• [83]Zhan X, Giorgianni F, Desiderio DM: Proteomics analysis of growth hormone isoforms in the human pituitary. Proteomics 2005, 5:1228-1241.
• [84]Zeng GQ, Zhang PF, Deng X, Yu FL, Li C, Xu Y, Yi H, Li MY, Hu R, Zuo JH, Li XH, Wan XX, Qu JQ, He QY, Li JH, Ye X, Chen Y, Li JY, Xiao ZQ: Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol Cell Proteomics 2012, 11:M111 013946.
• [85]Marzinke MA, Choi CH, Chen L, Shih IM, Chan DW, Zhang H: Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. Mol Cell Proteomics 2012.
• [86]Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, Jensen LJ: STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2012.
• [87]De Las RJ, Prieto C: Protein interactions: mapping interactome networks to support drug target discovery and selection. Methods Mol Biol 2012, 910:279-296.
• [88]Schmidt C: Metabolomics takes its place as latest up-and-coming “omic” science. J Natl Cancer Inst 2004, 96:732-734.
• [89]Vadigepalli R, Chakravarthula P, Zak DE, Schwaber JS, Gonye GE: PAINT: a promoter analysis and interaction network generation tool for gene regulatory network identification. OMICS 2003, 7:235-252.
• [90]Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004, 23:2934-2949.
• [91]Chen R, Snyder M: Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med 2013, 5:73-82.
• [92]Ginsburg GS, Kuderer NM: Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. J Clin Oncol 2012, 30:4233-4242.
• [93]Qattan M, Demonacos C, Krstic-Demonacos M: Roadmap to personalized medicine. Croat Med J 2012, 53:294-297.
• [94]Hood L: Systems biology: integrating technology, biology, and computation. Mech Ageing Dev 2003, 124:9-16.
• [95]Aderem A: Systems biology: its practice and challenges. Cell 2005, 121:511-513.
• [96]Hood L, Tian Q: Systems approaches to biology and disease enable translational systems medicine. Genomics Proteomics Bioinformatics 2012, 10:181-185.
• [97]Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by invitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999, 17:1625-1631.
• [98]Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.